Ranbaxy’s GMP Woes Puts Spotlight On Daiichi Sankyo Due Diligence
This article was originally published in PharmAsia News
Executive Summary
Whether Daiichi Sankyo will be able to claim damages from Ranbaxy’s former owners will depend on what Daiichi Sankyo knew before the acquisition, and its chances of proving misrepresentation may be slim.